OncoMatch/Clinical Trials/NCT05305859
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
Is NCT05305859 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies venetoclax combining chidamide and azacitidine (VCA) for leukemia, myeloid, acute.
Treatment: venetoclax combining chidamide and azacitidine (VCA) — The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Kidney function
Creatinine clearance≥30 mL/min and serum Creatinine ≤ 160µmol/L
Liver function
ALT and AST ≤ 3 × upper limit of normal (ULN)
Cardiac function
No uncontrolled or significant cardiovascular disease, including: bradycardia <50 bpm (unless pacemaker), long QT syndrome, SBP ≥180 mmHg or DBP ≥110 mmHg, ventricular arrhythmias, Mobitz II or third degree heart block (unless pacemaker and no symptoms), uncontrolled angina or MI within 6 months, NYHA Class 3 or 4 heart failure, complete LBBB, LVEF ≤45% or below institutional lower limit
Adequate laboratory parameters during the screening period as evidenced by the following: Creatinine clearance≥30 mL/min and serum Creatinine ≤ 160µmol/L; ALT and AST ≤ 3 × upper limit of normal (ULN); Known history of left ventricular ejection fraction (LVEF) ≤45% or less than the institutional lower limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify